دورية أكاديمية
A GMP-compliant manufacturing method for Wharton's jelly-derived mesenchymal stromal cells.
العنوان: | A GMP-compliant manufacturing method for Wharton's jelly-derived mesenchymal stromal cells. |
---|---|
المؤلفون: | Chu W; Shenzhen Beike Biotechnology Co., Ltd, 518000, Shenzhen, Guangdong, People's Republic of China., Zhang F; Shenzhen Beike Biotechnology Co., Ltd, 518000, Shenzhen, Guangdong, People's Republic of China., Zeng X; Shenzhen Beike Biotechnology Co., Ltd, 518000, Shenzhen, Guangdong, People's Republic of China., He F; Shenzhen Beike Biotechnology Co., Ltd, 518000, Shenzhen, Guangdong, People's Republic of China., Shang G; Shenzhen Beike Biotechnology Co., Ltd, 518000, Shenzhen, Guangdong, People's Republic of China., Guo T; Shenzhen Beike Biotechnology Co., Ltd, 518000, Shenzhen, Guangdong, People's Republic of China., Wang Q; Shenzhen Beike Biotechnology Co., Ltd, 518000, Shenzhen, Guangdong, People's Republic of China., Wu J; Shenzhen Beike Biotechnology Co., Ltd, 518000, Shenzhen, Guangdong, People's Republic of China., Li T; Shenzhen Beike Biotechnology Co., Ltd, 518000, Shenzhen, Guangdong, People's Republic of China., Zhong ZZ; Shenzhen Beike Biotechnology Co., Ltd, 518000, Shenzhen, Guangdong, People's Republic of China., Liang X; Shenzhen Beike Biotechnology Co., Ltd, 518000, Shenzhen, Guangdong, People's Republic of China., Hu J; Shenzhen Beike Biotechnology Co., Ltd, 518000, Shenzhen, Guangdong, People's Republic of China. sean.hu@beike.cc., Liu M; National Engineering Research Center of Foundational Technologies for CGT Industry, 518000, Shenzhen, Guangdong, People's Republic of China. liumuyun@nlelpct.com.; Shenzhen Kenuo Medical Laboratory, 518000, Shenzhen, Guangdong, People's Republic of China. liumuyun@nlelpct.com. |
المصدر: | Stem cell research & therapy [Stem Cell Res Ther] 2024 May 03; Vol. 15 (1), pp. 131. Date of Electronic Publication: 2024 May 03. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 101527581 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-6512 (Electronic) Linking ISSN: 17576512 NLM ISO Abbreviation: Stem Cell Res Ther Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: London : BioMed Central |
مواضيع طبية MeSH: | Mesenchymal Stem Cells*/cytology , Mesenchymal Stem Cells*/metabolism , Wharton Jelly*/cytology, Humans ; Cell Culture Techniques/methods ; Cell Differentiation ; Cells, Cultured ; Cell Proliferation ; Cell Separation/methods ; Cell Separation/standards |
مستخلص: | Background: Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) hold great therapeutic potential in regenerative medicine. Therefore, it is crucial to establish a Good Manufacturing Practice (GMP)-compliant methodology for the isolation and culture of WJ-MSCs. Through comprehensive research, encompassing laboratory-scale experiments to pilot-scale studies, we aimed to develop standardized protocols ensuring the high yield and quality of WJ-MSCs manufacturing. Methods: Firstly, optimization of parameters for the enzymatic digestion method used to isolate WJ-MSCs was conducted. These parameters included enzyme concentrations, digestion times, seeding densities, and culture media. Additionally, a comparative analysis between the explant method and the enzymatic digestion method was performed. Subsequently, the consecutive passaging of WJ-MSCs, specifically up to passage 9, was evaluated using the optimized method. Finally, manufacturing processes were developed and scaled up, starting from laboratory-scale flask-based production and progressing to pilot-scale cell factory-based production. Furthermore, a stability study was carried out to assess the storage and use of drug products (DPs). Results: The optimal parameters for the enzymatic digestion method were a concentration of 0.4 PZ U/mL Collagenase NB6 and a digestion time of 3 h, resulting in a higher yield of P0 WJ-MSCs. In addition, a positive correlation between the weight of umbilical cord tissue and the quantities of P0 WJ-MSCs has been observed. Evaluation of different concentrations of human platelet lysate revealed that 2% and 5% concentrations resulted in similar levels of cell expansion. Comparative analysis revealed that the enzymatic digestion method exhibited faster outgrowth of WJ-MSCs compared to the explant method during the initial passage. Passages 2 to 5 exhibited higher viability and proliferation ability throughout consecutive passaging. Moreover, scalable manufacturing processes from the laboratory scale to the pilot scale were successfully developed, ensuring the production of high-quality WJ-MSCs. Multiple freeze-thaw cycles of the DPs led to reduced cell viability and viable cell concentration. Subsequent thawing and dilution of the DPs resulted in a significant decrease in both metrics, especially when stored at 20-27 °C. Conclusion: This study offers valuable insights into optimizing the isolation and culture of WJ-MSCs. Our scalable manufacturing processes facilitate the large-scale production of high-quality WJ-MSCs. These findings contribute to the advancement of WJ-MSCs-based therapies in regenerative medicine. (© 2024. The Author(s).) |
References: | Stem Cells. 2005 Feb;23(2):220-9. (PMID: 15671145) Int J Stem Cells. 2021 Feb 28;14(1):103-111. (PMID: 33377453) Stem Cell Rev Rep. 2022 Jun;18(5):1525-1545. (PMID: 35344199) Stem Cell Res Ther. 2022 Apr 4;13(1):142. (PMID: 35379348) Front Cell Dev Biol. 2021 Apr 13;9:648472. (PMID: 33928083) Toxicol In Vitro. 2015 Sep;29(6):1254-62. (PMID: 25541070) Stem Cell Res Ther. 2021 Feb 26;12(1):152. (PMID: 33637125) Stem Cell Res Ther. 2020 May 19;11(1):183. (PMID: 32430063) J Transl Med. 2020 Sep 15;18(1):351. (PMID: 32933520) Drug Des Devel Ther. 2021 Sep 15;15:3927-3936. (PMID: 34584402) Cell Immunol. 2011;272(1):33-8. (PMID: 22004796) Biomaterials. 2016 Jan;76:371-87. (PMID: 26561934) Cells. 2021 May 26;10(6):. (PMID: 34073206) Sci Rep. 2021 Feb 9;11(1):3403. (PMID: 33564114) Stem Cells Transl Med. 2020 Oct;9(10):1137-1146. (PMID: 32531111) Stem Cells Dev. 2011 Jan;20(1):53-66. (PMID: 20528146) Cytotherapy. 2009;11(7):958-72. (PMID: 19903107) Neurochem Res. 2020 Jan;45(1):204-214. (PMID: 31828497) Eur J Cell Biol. 2002 Jun;81(6):313-21. (PMID: 12113472) Cell Tissue Bank. 2016 Jun;17(2):289-302. (PMID: 26679929) Cells. 2019 May 21;8(5):. (PMID: 31117301) J Clin Med. 2020 Apr 12;9(4):. (PMID: 32290584) Environ Mol Mutagen. 2004;43(1):36-44. (PMID: 14743344) Stem Cells Int. 2017;2017:6597815. (PMID: 29158740) Stem Cell Res Ther. 2020 Aug 8;11(1):345. (PMID: 32771052) Stem Cell Res Ther. 2021 Nov 13;12(1):571. (PMID: 34774107) Tissue Eng Regen Med. 2021 Feb;18(1):15-23. (PMID: 33150562) Haematologica. 2006 Aug;91(8):1017-26. (PMID: 16870554) Cells. 2021 Apr 28;10(5):. (PMID: 33925059) Cytotherapy. 2020 Oct;22(10):581-591. (PMID: 32718875) J Biol Eng. 2023 Jul 11;17(1):44. (PMID: 37434264) Stem Cell Res Ther. 2018 May 2;9(1):124. (PMID: 29720245) Stem Cell Res Ther. 2018 May 2;9(1):121. (PMID: 29720263) World J Stem Cells. 2014 Apr 26;6(2):195-202. (PMID: 24772246) J Orthop Res. 1991 Sep;9(5):641-50. (PMID: 1870029) Cells. 2022 Jul 22;11(15):. (PMID: 35892560) Pathol Res Pract. 1984 Mar;178(4):315-22. (PMID: 6728713) Cytotherapy. 2016 Feb;18(2):151-9. (PMID: 26724220) Vaccine. 2014 Nov 28;32(50):6820-7. (PMID: 25086263) Int J Mol Med. 2014 Feb;33(2):263-70. (PMID: 24297321) Cytotherapy. 2006;8(4):315-7. (PMID: 16923606) Int J Med Sci. 2018 May 22;15(8):771-781. (PMID: 30008586) Cytometry A. 2018 Jan;93(1):19-31. (PMID: 29072818) Cytotechnology. 2013 Oct;65(5):819-27. (PMID: 23306781) Cytotherapy. 2008;10(2):125-33. (PMID: 18368591) Science. 1999 Apr 2;284(5411):143-7. (PMID: 10102814) Methods Mol Biol. 2016;1416:159-69. (PMID: 27236671) Front Bioeng Biotechnol. 2021 Jan 15;8:598389. (PMID: 33520956) J Clin Med. 2019 Dec 14;8(12):. (PMID: 31847319) Curr Stem Cell Res Ther. 2017;12(6):484-492. (PMID: 27133085) Curr Res Transl Med. 2022 Sep;70(4):103353. (PMID: 35940083) Cytotherapy. 2019 Apr;21(4):483-495. (PMID: 30879965) Stem Cell Res Ther. 2012 Feb 14;3(1):6. (PMID: 22333342) Stem Cells. 2006 Feb;24(2):462-71. (PMID: 16109759) Cell Stem Cell. 2015 Jul 2;17(1):11-22. (PMID: 26140604) Front Cell Dev Biol. 2021 Feb 16;9:632717. (PMID: 33665190) Stem Cells Int. 2016;2016:6810980. (PMID: 26966439) Stem Cell Res Ther. 2019 Nov 28;10(1):354. (PMID: 31779707) Stem Cells Transl Med. 2017 Jul;6(7):1620-1630. (PMID: 28488282) Sci Adv. 2020 Jul 22;6(30):eaba6884. (PMID: 32832666) Cell Prolif. 2009 Jun;42(3):276-83. (PMID: 19438895) Stem Cells. 2006 Apr;24(4):928-35. (PMID: 16306150) Cell Tissue Kinet. 1970 Oct;3(4):393-403. (PMID: 5523063) Stem Cell Res Ther. 2018 May 11;9(1):131. (PMID: 29751774) Stem Cells. 2020 Aug;38(8):1034-1049. (PMID: 32379908) Methods Mol Biol. 2008;449:83-91. (PMID: 18370085) PLoS One. 2014 Apr 15;9(4):e93726. (PMID: 24736473) Cell Commun Signal. 2023 Feb 14;21(1):36. (PMID: 36788616) Biomed Res Int. 2014;2014:951512. (PMID: 24511552) Trends Biotechnol. 2020 Jan;38(1):13-23. (PMID: 31326128) Cells Tissues Organs. 2019;207(3-4):149-164. (PMID: 31593940) Curr Res Transl Med. 2023 Apr-Jun;71(2):103393. (PMID: 37163885) Gene X. 2020 Mar 14;5:100031. (PMID: 32550557) Cytotherapy. 2017 Dec;19(12):1351-1382. (PMID: 28964742) Curr Res Transl Med. 2020 Jan;68(1):5-16. (PMID: 31543433) Curr Protoc Stem Cell Biol. 2017 May 16;41:1F.18.1-1F.18.23. (PMID: 28510332) Front Cell Dev Biol. 2022 Oct 12;10:1006295. (PMID: 36313578) Int J Mol Sci. 2021 May 13;22(10):. (PMID: 34068404) Sci Rep. 2020 Nov 4;10(1):18978. (PMID: 33149204) Front Cell Dev Biol. 2021 May 03;9:570179. (PMID: 34012958) |
فهرسة مساهمة: | Keywords: Enzymatic digestion; Good manufacturing practice; Mesenchymal stem cells; Scale-up; Stability; Wharton jelly |
تواريخ الأحداث: | Date Created: 20240503 Date Completed: 20240504 Latest Revision: 20240507 |
رمز التحديث: | 20240507 |
مُعرف محوري في PubMed: | PMC11069138 |
DOI: | 10.1186/s13287-024-03725-0 |
PMID: | 38702793 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1757-6512 |
---|---|
DOI: | 10.1186/s13287-024-03725-0 |